Last reviewed · How we verify
Nelfinavir (NFV)
Nelfinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.
Nelfinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles. Used for HIV-1 infection (in combination antiretroviral therapy), Pediatric HIV-1 infection.
At a glance
| Generic name | Nelfinavir (NFV) |
|---|---|
| Also known as | Viracept |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Nelfinavir binds to the active site of HIV protease, a viral enzyme essential for processing precursor proteins into functional structural and enzymatic proteins. By inhibiting this protease, the drug prevents the formation of mature, infectious viral particles, thereby reducing viral replication and slowing disease progression. It is typically used as part of combination antiretroviral therapy (cART) in HIV-infected patients.
Approved indications
- HIV-1 infection (in combination antiretroviral therapy)
- Pediatric HIV-1 infection
Common side effects
- Diarrhea
- Nausea
- Rash
- Hyperglycemia
- Lipid abnormalities
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (PHASE3)
- Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow (PHASE1, PHASE2)
- Autophagy Maintenance (AUTOMAIN) (PHASE2)
- Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery (PHASE1)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |